通策医疗（600763）1月29日主力资金净买入1.17亿元

Core Viewpoint - Tongce Medical (600763) has shown a positive performance with a closing price of 47.49 yuan, reflecting a 5.14% increase as of January 29, 2026, with significant trading volume and turnover [1] Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders reached 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, a 2.34% year-on-year increase, and a net profit of 192 million yuan, up 2.31% [3] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, resulting in a gross profit margin of 41.69% [3] Market Activity - On January 29, 2026, the net inflow of main funds was 117 million yuan, accounting for 12.09% of the total turnover, while retail investors experienced a net outflow of approximately 57.90 million yuan [1] - The financing data indicates a financing buy of 67.31 million yuan and a financing repayment of 80.66 million yuan, resulting in a net repayment of 13.34 million yuan [2] - The stock has received ratings from four institutions in the last 90 days, with two buy ratings and two hold ratings, and the average target price set at 51.1 yuan [3]